Literature DB >> 21510829

Targeted therapies in bone sarcomas: current approach and future directions.

Jessica Lee Yarber1, Mark Agulnik.   

Abstract

INTRODUCTION: Bone sarcomas are rare malignancies and once advanced, there is limited response to current chemotherapeutic regimens. Targeted therapies could have substantial impact on these diseases. AREAS COVERED: Specific molecular targets of bone sarcomas are reviewed along with the various targeted therapies that have potential to change the outcome of these chemotherapy resistant diseases. EXPERT OPINION: There are promising pathways identified that targeted inhibitors could provide better treatment options for metastatic bone sarcomas. There is a strong need for continued Phase II and III clinical trials investigating these molecularly targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21510829     DOI: 10.1517/13543784.2011.577064

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

1.  Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors.

Authors:  Fengbin Yu; Jinhao Miao
Journal:  Tumour Biol       Date:  2013-07-31

2.  Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis.

Authors:  Liangdong Jiang; Cheng Tao; Aiyong He
Journal:  Tumour Biol       Date:  2013-01-23

3.  Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas.

Authors:  Changchun Fan; Xuechun Zhao; Zhixing Xu
Journal:  Tumour Biol       Date:  2014-09-18

4.  Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells.

Authors:  Changbao Chen; Meng Zhao; Aixian Tian; Xiaolin Zhang; Zhi Yao; Xinlong Ma
Journal:  Oncotarget       Date:  2015-07-10

5.  Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells.

Authors:  Mei Li; Ye Zhu; Hongbin Zhang; Lihua Li; Peng He; Hong Xia; Yu Zhang; Chuanbin Mao
Journal:  Sci Rep       Date:  2014-12-09       Impact factor: 4.379

6.  Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma.

Authors:  Xu Hu; Chao Zhang; Ying Zhang; Christopher S Hong; Wugui Chen; Weiwei Shen; Hongkai Wang; Jianrong He; Pei Chen; Yue Zhou; Chunmeng Shi; Tongwei Chu
Journal:  Oncotarget       Date:  2017-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.